Clinical comparison of the biosimilar ABP 980 and trastuzumab in early breast cancer: Results of the phase 3 LILAC study and justification for extrapolation across approved trastuzumab indications

被引：0
|
作者：
Kolberg, H. C. [1 ]
Tomasevic, Z. [2 ]
Demetriou, G. S. [3 ]
Von Minckwitz, G. [4 ]
Fujiwara, Y. [5 ]
Ponomarova, O. [6 ]
Tesch, H. [7 ]
Santi, P. [8 ]
Hanes, V. [9 ]
机构：
[1] Marienhospital gGmbH, Klin Gynakol & Geburtshilfe, Bottrop, Germany
[2] Inst Oncol & Radiol Serbia, Oncol & Radiol, Belgrade, Serbia
[3] Charlotte Mexeke Johannesburg Acad Hosp, Div Med Oncol, Johannesburg, South Africa
[4] German Breast Grp, Neu Isenburg, Germany
[5] Natl Canc Ctr, Tokyo, Japan
[6] RE Kavetsky Inst Expt Pathol, Expt Pathol, Kiev, Ukraine
[7] Hamatol Onkol Gemeinschaftspraxis, Frankfurt, Germany
[8] Ctr Estudos Hematol & Oncol, Hematol & Oncol, Sao Paulo, Brazil
[9] Amgen Inc, Biosimilars Global Dev, Thousand Oaks, CA 91320 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2018年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
365 (PB-16
引用
收藏
页码：S103 / S104
页数：2
相关论文
共 50 条
  • [1] Matching the critical function of the biosimilar ABP 980 and trastuzumab: Totality of evidence and scientific justification for extrapolation across trastuzumab indications
    Kolberg, H-C
    Colleoni, M. A.
    Tomasevic, Z.
    Ponomarova, O.
    McBride, H. J.
    Tesch, H.
    Hanes, V.
    CANCER RESEARCH, 2019, 79 (04)
  • [2] Biosimilar ABP 980 in patients with early breast cancer: Results of single switch from trastuzumab to ABP 980
    von Minckwitz, Gunter
    Turdean, Maria
    Zhang, Nan
    Santi, Patricia
    Hanes, Vladimir
    CANCER RESEARCH, 2018, 78 (04)
  • [3] CARDIAC SAFETY OF THE TRASTUZUMAB BIOSIMILAR ABP 980 IN WOMEN WITH HER2-POSITIVE EARLY BREAST CANCER IN THE LILAC STUDY
    Kolberg, H-C
    Colleoni, M.
    Demetriou, G. Sawa
    Santi, P.
    Tesch, H.
    Fujiwara, Y.
    Tomasevic, Z.
    Hanes, V.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A55 - A55
  • [4] Cardiac safety of the trastuzumab biosimilar ABP 980 in women with HER2-positive early breast cancer in the LILAC study.
    Kolberg, Hans-Christian
    Colleoni, Marco
    Demetriou, Georgia
    Santi, Patricia Xavier
    Tesch, Hans
    Fujiwara, Yasuhiro
    Tomasevic, Zorica
    Hanes, Vladimir
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Efficacy analyses of central laboratory pCR results from the LILAC study comparing the biosimilar ABP 980 and trastuzumab
    Kolberg, Hans-Christian
    Tomasevic, Zorica
    Demetriou, Georgia
    Fujiwara, Yasuhiro
    Colleoni, Marco
    Tesch, Hans
    Santi, Patricia Xavier
    Hanes, Vladimir
    Zhang, Nan
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Efficacy and safety of biosimilar ABP 980 compared with trastuzumab in HER2 positive early breast cancer
    von Minckwitz, G.
    Ponomarova, O.
    Morales, S.
    Zhang, N.
    Hanes, V.
    ANNALS OF ONCOLOGY, 2017, 28
  • [7] Comparison of Biosimilar Trastuzumab ABP 980 with Reference Trastuzumab in Neoadjuvant Therapy for HER2-positive Breast Cancer - an Analysis of a Large University Breast Cancer Centre
    Matovina, Sabine
    Engler, Tobias
    Volmer, Lea-Louise
    Mueller, Heike
    Grischke, Eva-Maria
    Staebler, Annette
    Hahn, Markus
    Brucker, Sara Yvonne
    Hartkopf, Andreas Daniel
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2023, 83 (06) : 694 - 701
  • [8] Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study
    Hans-Christian Kolberg
    Marco Colleoni
    Georgia Savva Demetriou
    Patricia Santi
    Hans Tesch
    Yasuhiro Fujiwara
    Zorica Tomasevic
    Vladimir Hanes
    Drug Safety, 2020, 43 : 233 - 242
  • [9] Cardiac Safety of the Trastuzumab Biosimilar ABP 980 in Women with HER2-Positive Early Breast Cancer in the Randomized, Double-Blind, Active-Controlled LILAC Study
    Kolberg, Hans-Christian
    Colleoni, Marco
    Demetriou, Georgia Savva
    Santi, Patricia
    Tesch, Hans
    Fujiwara, Yasuhiro
    Tomasevic, Zorica
    Hanes, Vladimir
    DRUG SAFETY, 2020, 43 (03) : 233 - 242
  • [10] Safety results from a randomized, double-blind, phase 3 study of ABP 980 compared with trastuzumab in patients with breast cancer
    Kolberg, Hans-Christian
    Demetriou, Georgia S.
    Zhang, Nan
    Tomasevic, Zorica
    Hanes, Vladimir
    CANCER RESEARCH, 2018, 78 (04)
12345